Top FDA staffer becomes third to resign since August

An FDA official, whose office was involved in the recent controversial approval review of Bristol-Myers Squibb's Pargluva, has announced his resignation to join private industry, The New York Times reports.
David Orloff, a division director who oversees the review of drugs to treat metabolic and endocrine disorders, is set to join Medpace, a contract research organization that runs clinical drug trials.
Orloff told the Times his decision to leave after 11 years at the FDA, with five of them as division director, was not related to any problems or frustrations, but reflected a new opportunity. 
Orloff's departure from the FDA will be the third by a ranking agency official since the summer. In September, FDA commissioner Lester Crawford resigned for reasons yet to be fully explained, and in August, Susan Wood, the agency's top women's health official, resigned in protest over delays in an approval decision for the OTC sale of Barr's Plan B contraceptive

You must be a registered member of MMM to post a comment.

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters